Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Rapid Anti-Depressant Response Produced by Low Dose Treatment with Anti-Muscarinic Drugs
Case ID:
TAB-1294
Web Published:
12/6/2022
Available for licensing are new methods of rapidly treating depression. The drugs currently used to treat depression work by increasing the activity at serotonin, norepinephrine and perhaps dopamine receptors in the CNS. However these drugs are effective in only 60-70% of patients, require 3-4 weeks of treatment before clinical improvement and have many side effects. These inventors have shown that in human patients, the administration of anti-muscarinic agents produces a rapid, prolonged alleviation of depressive symptoms. Beginning the day following administration of the anti-muscarinic agent, a majority of patients show significant improvements in mood, anxiety, sleep and other depressive symptoms that last days or weeks. The very slow dissociation of some muscarinic agents from their receptors may account for the prolonged therapeutic effects.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Direct Link:
https://canberra-ip.technologypublisher.com/tech/Rapid_Anti-Depressant_Respon se_Produced_by_Low_Dose_Treatment_with_Anti-Muscarinic_Drugs
Keywords:
NB2AXX
NB2DXX
NBXXXX
NXXXXX
Bookmark this page
Download as PDF
For Information, Contact:
Jennifer Wong
Technology Development Coordinator
NIH Technology Transfer
301-828-3707
jennifer.wong2@nih.gov